Advertisement

Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure

Published:October 10, 2019DOI:https://doi.org/10.1016/j.amjcard.2019.09.039
      Although torsemide's oral bioavailability and half-life theoretically render it a more efficient diuretic than furosemide, the clinical outcomes of torsemide compared with furosemide remain unclear. We performed a systematic review and meta-analysis, including all published studies that compared torsemide and furosemide use in heart failure patients from January 1996 through August 2019. Nineteen studies (9 randomized control trials [RCTs] and 10 observational studies) with a total of 19,280 patients were included. During a mean follow-up duration of 15 months, torsemide was associated with a numerically lower risk of hospitalization due to heart failure (10.6% vs 18.4%; odds ratio [OR] 0.72, 95% confidence interval [CI] [0.51, 1.03], p = 0.07, I2 = 18%; number needed to treat [NNT] = 23) compared with furosemide. Torsemide was associated with statistically significant more improvement in functional status from New York Heart Association (NYHA) class III/IV to I/II (72.5% vs 58%; OR 2.32, 95% CI (1.32, 4.1), p = 0.004, I2 = 27%; NNT = 5) and lower risk of cardiac mortality (1.5% vs 4.4%; OR 0.37, 95% CI (0.20, 0.66), p <0.001, I2 = 0%, NNT = 40) compared with furosemide. However, there was no difference in all-cause mortality or medication side effects between the 2 groups. In conclusion, compared with furosemide, torsemide use was associated with significant more improvement in functional status and lower cardiac mortality; and numerically fewer hospitalizations in patients with heart failure.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Benjamin EJ
        • Muntner P
        • Bittencourt MS
        Heart disease and stroke statistics-2019 update: a report from the American Heart Association.
        Circulation. 2019; 139: e56-e528
        • Savarese G
        • Lund LH
        Global public health burden of heart failure.
        Card Fail Rev. 2017; 3: 7-11
        • Yancy CW
        • Jessup M
        • Bozkurt B
        • Butler J
        • Casey DE
        • Drazner MH
        • Fonarow GC
        • Geraci SA
        • Horwich T
        • Januzzi JL
        2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines.
        JACC. 2013; 62: e147-e239
        • Faris R
        • Flather M
        • Purcell H
        • Henein M
        • Poole-Wilson P
        • Coats A
        Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials.
        Int J Cardiol. 2002; 82: 149-158
        • López B
        • Querejeta R
        • González A
        • Sánchez E
        • Larman M
        • Díez J
        Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure.
        JACC. 2004; 43: 2028-2035
        • Kasama S
        • Toyama T
        • Hatori T
        • Sumino H
        • Kumakura H
        • Takayama Y
        • Ichikawa S
        • Suzuki T
        • Kurabayashi M
        Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure.
        Heart. 2006; 92: 1434-1440
        • Müller K
        • Gamba G
        • Jaquet F
        • Hess B
        Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV—efficacy and quality of life.
        Eur J Heart Fail. 2003; 5: 793-801
        • Murray MD
        • Deer MM
        • Ferguson JA
        • Dexter PR
        • Bennett SJ
        • Perkins SM
        • Smith FE
        • Lane KA
        • Adams LD
        • Tierney WM
        Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure.
        Am J Med. 2001; 111: 513-520
        • Noe LL
        • Vreeland MG
        • Pezzella SM
        • Trotter JP
        A pharmacoeconomic assessment of torsemide and furosemide in the treatment of patients with congestive heart failure.
        Clin Ther. 1999; 21: 854-866
        • Group TTI
        Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded–end point, active-controlled study.
        Clin Ther. 2011; 33: 1204-1213
        • Yamato M
        • Sasaki T
        • Honda K
        • Fukuda M
        • Akutagawa O
        • Okamoto M
        • Hayashi T
        Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure.
        Circ J. 2003; 67: 384-390
        • Stauch M
        • Stiehl M.
        Controlled double blind clinical trial on the efficacy and tolerance of torasemide in patients with congestive heart failure. A multi-center study.
        Progress in Pharmacology and Clinical Pharmacology Gustav-Fischer-Verlag: Stuttgart. 1990; 8: 121-126
        • Trippel TD
        • Van Linthout S
        • Westermann D
        • Lindhorst R
        • Sandek A
        • Ernst S
        • Bobenko A
        • Kasner M
        • Spillmann F
        • Gonzalez A
        Investigating a biomarker‐driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C‐terminal propeptide of procollagen type I (DROP‐PIP trial).
        Eur J Heart Fail. 2018; 20: 460-470
        • Cosín J
        • Díez J
        TORIC investigators obot. Torasemide in chronic heart failure: results of the TORIC study.
        Eur J Heart Fail. 2002; 4: 507-513
        • Han L
        • Guo S
        • Lin X
        • Shi X
        • Zang C
        • Yang L
        • Ding G
        Torasemide reduces dilated cardiomyopathy, complication of arrhythmia, and progression to heart failure.
        Genet Mol Res. 2014; 13: 7262-7274
        • Mentz RJ
        • Buggey J
        • Fiuzat M
        • Ersbøll MK
        • Schulte PJ
        • DeVore AD
        • Eisenstein EL
        • Anstrom KJ
        • O'Connor CM
        • Velazquez EJ
        Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital.
        J Cardiovasc Pharmacol. 2015; 65: 438-443
        • Mentz RJ
        • Hasselblad V
        • DeVore AD
        • Metra M
        • Voors AA
        • Armstrong PW
        • Ezekowitz JA
        • Tang WW
        • Schulte PJ
        • Anstrom KJ
        Torsemide versus furosemide in patients with acute heart failure (from the ASCEND-HF Trial).
        Am J Cardiol. 2016; 117: 404-411
        • Mentz RJ
        • Velazquez EJ
        • Metra M
        • McKendry C
        • Chiswell K
        • Fiuzat M
        • Givertz MM
        • Voors AA
        • Teerlink JR
        • O'Connor CM
        Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial.
        Future Cardiol. 2015; 11: 585-595
        • Spannheimer A
        • Goertz A
        • Dreckmann-Behrendt B
        Comparison of therapies with torasemide or furosemide in patients with congestive heart failure from a pharmacoeconomic viewpoint.
        Int J Clin Pract. 1998; 52: 467-471
        • Yao Y
        • Zhang J
        • Zhang Y
        • Zhang R
        Can torsemide and combination of loop diuretics improve mortality in patients with chronic heart failure after discharge?.
        Int Heart J. 2018; 59: 813-820
        • Ozierański K
        • Balsam P
        • Kapłon-Cieślicka A
        • Tymińska A
        • Kowalik R
        • Grabowski M
        • Peller M
        • Wancerz A
        • Marchel M
        • Crespo-Leiro MG
        Comparative analysis of long-term outcomes of torasemide and furosemide in heart failure patients in heart failure registries of the European Society of Cardiology.
        Cardiovasc Drugs Ther. 2019; 33: 77-86
        • Rahhal A
        • Saad MO
        • Tawengi K
        • Assi AAR
        • Habra M
        • Ahmed D
        Torsemide versus furosemide after acute decompensated heart failure: a retrospective observational study.
        BMC Cardiovasc Disord. 2019; 19: 127-134
        • Täger T
        • Fröhlich H
        • Grundtvig M
        • Seiz M
        • Schellberg D
        • Goode K
        • Kazmi S
        • Hole T
        • Katus HA
        • Atar D
        Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure—a multicenter propensity score matched analysis.
        Int J Cardiol. 2019; 289: 83-90
        • Vaccarino V
        • Kasl SV
        • Abramson J
        • Krumholz HM
        Depressive symptoms and risk of functional decline and death in patients with heart failure.
        JACC. 2001; 38: 199-205
        • Austin J
        • Williams R
        • Ross L
        • Moseley L
        • Hutchison S
        Randomised controlled trial of cardiac rehabilitation in elderly patients with heart failure.
        Eur J Heart Fail. 2005; 7: 411-417
        • Vargo DL
        • Kramer WG
        • Black PK
        • Smith WB
        • Serpas T
        • Brater DC
        Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure.
        Clin Pharmacol Ther. 1995; 57: 601-609
        • Tsutamoto T
        • Sakai H
        • Wada A
        • Ishikawa C
        • Ohno K
        • Fujii M
        • Yamamoto T
        • Takayama T
        • Dohke T
        • Horie M
        Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure.
        JACC. 2004; 44: 2252-2253
        • Pitt B
        • Zannad F
        • Remme WJ
        • Cody R
        • Castaigne A
        • Perez A
        • Palensky J
        • Wittes J
        The effect of spironolactone on morbidity and mortality in patients with severe heart failure.
        N Engl J Med. 1999; 341: 709-717
        • Selvaraj S
        • Claggett B
        • Pozzi A
        • McMurray JJ
        • Jhund PS
        • Packer M
        • Desai AS
        • Lewis EF
        • Vaduganathan M
        • Lefkowitz MP
        Prognostic implications of congestion on physical examination among contemporary patients with heart failure and reduced ejection fraction: PARADIGM-HF.
        Circulation. 2019; 140: 1369-1379
        • Pocock SJ
        • Wang D
        • Pfeffer MA
        • Yusuf S
        • McMurray JJ
        • Swedberg KB
        • Ostergren J
        • Michelson EL
        • Pieper KS
        • Granger CB
        Predictors of mortality and morbidity in patients with chronic heart failure.
        Eur Heart J. 2005; 27: 65-75